Exact Mass: 457.27799760000005

Exact Mass Matches: 457.27799760000005

Found 500 metabolites which its exact mass value is equals to given mass value 457.27799760000005, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

10,11-Dihydro-12R-hydroxy-leukotriene E4

(5S,6R,7E,9E,12S,14Z)-6-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}-5,12-dihydroxyicosa-7,9,14-trienoic acid

C23H39NO6S (457.24979540000004)

10,11-dihydro-12R-hydroxy-leukotriene E4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 10,11-dihydro-12R-hydroxy-leukotriene E4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078)

N-Docosahexaenoyl Glutamic acid

2-[(1-Hydroxydocosa-4,7,10,13,16,19-hexaen-1-ylidene)amino]pentanedioate

C27H39NO5 (457.2828084)

N-docosahexaenoyl glutamic acid belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Glutamic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl Glutamic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl Glutamic acid is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

CENTCHROMAN

1-{2-[4-(7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-1-benzopyran-4-yl)phenoxy]ethyl}pyrrolidine

C30H35NO3 (457.26168000000007)

3-[2-(1,1-dimethyl-allyl)-4,5-bis-(3-methyl-but-2-enyl)-indol-3-ylmethylene]-6-methylene-piperazine-2,5-dione|Cryptoechinulin G|Kryptoechinulin

C29H35N3O2 (457.272913)

Spiramide

C26H35NO6 (457.24642500000004)

alkaloid E-7|Tetradehydroechinulin

C29H35N3O2 (457.272913)

SCHEMBL8411793

C26H35NO6 (457.24642500000004)

(3S,3aR,5R,5aS,6S,10aR,11R,12aS,12bS*)-5-acetoxy-5a-(acetoxymethyl)-2,3,3a,5,5a,6,7,8,9,10,10a,11,12,12b-tetradecahydro-3-methyl-4H-1,6-methanocyclopent[1,8]azuleno[4,3a-g]indole-11-carboxylic acid|macropodumine H

(3S*,3aR*,5R*,5aS*,6S*,10aR*,11R*,12aS*,12bS*)-5-acetoxy-5a-(acetoxymethyl)-2,3,3a,5,5a,6,7,8,9,10,10a,11,12,12b-tetradecahydro-3-methyl-4H-1,6-methanocyclopent[1,8]azuleno[4,3a-g]indole-11-carboxylic acid|macropodumine H

C26H35NO6 (457.24642500000004)

beta-Lipomycin

C26H35NO6 (457.24642500000004)

Piericidin A4

C28H43NO4 (457.31919180000006)

Sch 382582

C22H39N3O5S (457.26102840000004)

Lycognidin

C27H39NO5 (457.2828084)

C28H43NO4

C28H43NO4 (457.31919180000006)

(1aR,1bR,2R,3S,3R,3aS,5R,5aS,5bS,6S,7aR,10aS,10bS,10cS)-1a,1b,23a,4,4,5,5,5a,5b,6,7,7a,9,10,10a,10b,10c-octadecahydro-3,5-dihydroxy-3,5a,6,7-tetramethylspiro[8H-benzo[1,2]fluoreno[ 3,4-b]oxirene-8,2(3H)-furo[3,2-b]pyridin]-6(3H)-one

(1aR,1bR,2R,3S,3R,3aS,5R,5aS,5bS,6S,7aR,10aS,10bS,10cS)-1a,1b,23a,4,4,5,5,5a,5b,6,7,7a,9,10,10a,10b,10c-octadecahydro-3,5-dihydroxy-3,5a,6,7-tetramethylspiro[8H-benzo[1,2]fluoreno[ 3,4-b]oxirene-8,2(3H)-furo[3,2-b]pyridin]-6(3H)-one

C27H39NO5 (457.2828084)

clathrimide B

C23H39NO6S (457.24979540000004)

C26H35NO6

C26H35NO6 (457.24642500000004)

aspochalasin O

C27H39NO5 (457.2828084)

Arg Arg Leu